MS: Busting the Myths
September 14, 2022 | Advocacy, Progressive, Treatments
Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]
September 14, 2021 | Advocacy, Media, Study, Uncategorised
Media Release: 14 September 2021 (For Immediate Release) A new trans-Tasman study has highlighted alarming health inequities between New Zealand patients living with multiple sclerosis (MS) and their Australian counterparts — adding fuel to the ongoing fight for Pharmac to […]
August 3, 2021 | Education, Treatments, Uncategorised
The MS International Federation’s Atlas of MS showed that off-label disease-modifying therapies are used in at least 89 countries. This highlights the need for transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions. Because there has been […]
May 26, 2021 | Advocacy
Multiple Sclerosis NZ received several reports from concerned patients regarding the ambiguity of the Special Authority Criteria for DMTs. With the support of Dr John Mottershead, Pharmac were approached for clarification. Concern centred around whether bilateral aids qualify for use […]